Stoke is pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression. We develop antisense oligonucleotide medicines that increase gene expression to treat genetic epilepsies and other severe monogenic diseases, including genetic conditions affecting the central nervous system, eye, liver and kidney. We believe our proprietary technology platform, Targeted Augmentation of Nuclear Gene Output, or TANGO, will allow us to deliver disease-modifying therapies in a highly precise, durable and controlled manner.
August 4, 2020
July 9, 2020
June 4, 2020
Data Provided by Refinitiv. Minimum 15 minutes delayed.
August 12, 2020 at 2:30 PM EDT
August 11, 2020 at 2:00 PM EDT
August 11, 2020 at 11:30 AM EDT